Merck, Eisai's Two Phase 3 Trials Evaluating Keytruda (Pembrolizumab) Plus Lenvima (Lenvatinib) In Certain Types Of Metastatic Non-small Cell Lung Cancer Did Not Meet Its Dual Primary Endpoints Of Overall Survival And Progression-free Survival
Author: Benzinga Newsdesk | September 22, 2023 06:49am